SLAMF1 and tuberous sclerosis: The EXIST-2 (EXamining everolimus In a Study of Tuberous sclerosis complex) study demonstrated superiority of everolimus over placebo in angiomyolipoma response rate, time to angiomyolipoma progression, and skin lesion response rate in patients with angiomyolipoma associated with either TSC or sLAM [16,17].